Kinnate Biopharma Inc. Common Stock
KNTE
KNTE was delisted on the 2nd of April, 2024.
62 hedge funds and large institutions have $891M invested in Kinnate Biopharma Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 20 reducing their positions, and 9 closing their positions.
0% more funds holding
Funds holding: 62 → 62 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
15% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 20
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
24% less capital invested
Capital invested by funds: $1.18B → $891M (-$286M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$17.2M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$10.1M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.52M |
| 4 |
Morgan Stanley
New York
|
+$2.21M |
| 5 |
BlackRock
New York
|
+$1.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$7.79M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.17M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$5.03M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$3.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.98M |
KNTE Hedge Fund Activity: Q2 2021 in Review
62 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q2 2021, worth a combined $891M — down 24% from $1.18B a quarter earlier.
Fund positioning in KNTE was balanced in Q2 2021: 9 funds opened new positions, 9 closed out, 17 added to existing stakes and 20 trimmed.
The largest buyer was Deerfield Management, adding an estimated $17.2M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $7.79M sold.
- 62 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $891M of Kinnate Biopharma Inc. Common Stock stock for Q2 2021, down 24% quarter-over-quarter.
- 9 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q2 2021 and 9 closed out, a net change of 0 holders.
- The largest Kinnate Biopharma Inc. Common Stock buyer in Q2 2021 was Deerfield Management, an estimated $17.2M added.
- The largest Kinnate Biopharma Inc. Common Stock seller in Q2 2021 was Farallon Capital Management, an estimated $7.79M sold.
Based on aggregated 13F filings for Q2 2021.